Eusol Biotech Co.,Ltd.
Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company's pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel… Read more
Eusol Biotech Co.,Ltd. (6652) - Total Liabilities
Latest total liabilities as of June 2025: NT$8.10 Million TWD
Based on the latest financial reports, Eusol Biotech Co.,Ltd. (6652) has total liabilities worth NT$8.10 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eusol Biotech Co.,Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Eusol Biotech Co.,Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Eusol Biotech Co.,Ltd. Competitors by Total Liabilities
The table below lists competitors of Eusol Biotech Co.,Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TRP_AESTHETIC CONNECT
BK:TRP
|
Thailand | ฿96.20 Million |
|
Amanah Leasing Public Company Limited
BK:AMANAH
|
Thailand | ฿2.38 Billion |
|
Soktas Tekstil Sanayi ve Ticaret AS
IS:SKTAS
|
Turkey | TL1.66 Billion |
|
Impero AS
CO:IMPERO
|
Denmark | Dkr22.57 Million |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
USA | $91.69 Million |
|
Mercer Bancorp Inc.
OTCGREY:MSBB
|
USA | $152.89 Million |
|
JG Environmental Technology Co.,Ltd.
TWO:6723
|
Taiwan | NT$350.54 Million |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
India | ₹3.23 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Eusol Biotech Co.,Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 43.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eusol Biotech Co.,Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eusol Biotech Co.,Ltd. (2019–2024)
The table below shows the annual total liabilities of Eusol Biotech Co.,Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$7.48 Million | -19.36% |
| 2023-12-31 | NT$9.28 Million | -51.16% |
| 2022-12-31 | NT$18.99 Million | -9.03% |
| 2021-12-31 | NT$20.88 Million | +2.56% |
| 2020-12-31 | NT$20.36 Million | -23.28% |
| 2019-12-31 | NT$26.54 Million | -- |